Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucinations
1 other identifier
interventional
24
1 country
1
Brief Summary
The present study aims to investigate whether transcranial direct current stimulation (tDCS) reduces auditory hallucinations in patients with psychosis. In addition, the neuronal changes of tDCS will be examined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 6, 2016
CompletedFirst Posted
Study publicly available on registry
May 11, 2016
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedAugust 7, 2020
August 1, 2020
3.7 years
May 6, 2016
August 6, 2020
Conditions
Outcome Measures
Primary Outcomes (5)
Auditory Hallucination Rating Scale (AHRS)
Measure for severity of hallucinations
Change from Baseline to immediately after treatment and 3 months after treatment
Questionnaire for Psychotic Experiences (QPE)
Measure for severity of hallucinations
Change from Baseline to immediately after treatment and 3 months after treatment
Positive and Negative Syndrome Scale (PANSS)
Measure for positive and negative symptoms in psychotic disorders
Change from Baseline to immediately after treatment and 3 months after treatment
Hallucinations App
iPhone/iPod application for self-ratings of auditory hallucinations
Continuously between baseline and 3 months after treatment
Hallucination Change Scale (HCS)
Measure for changes in severity of auditory hallucinations
Change from Baseline to immediately after treatment and 3 months after treatment
Secondary Outcomes (13)
Stroop task
Change from Baseline to immediately after treatment and 3 months after treatment
Trailmaking test A and B
Change from Baseline to immediately after treatment and 3 months after treatment
Expectations Questionnaire
Change from Baseline to immediately after treatment and 3 months after treatment
Adverse Effects Questionnaire
The questionnaire is completed after each tDCS session. That is, twice on each day of the five day treatment program
The Clinical Global Impressions Scale - Severity
Change from Baseline to immediately after treatment and 3 months after treatment
- +8 more secondary outcomes
Study Arms (2)
real tDCS
EXPERIMENTALDC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
sham tDCS
SHAM COMPARATORDC Stimulator PLUS (NeuroConn) The sham condition is identical to the "real tDCS" condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period.
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosed with schizophrenia spectrum disorder or other psychotic disorder
- Frequent auditory hallucinations (at least 5 times a week).
- Patients are on a stable dose of antipsychotic medication (which can also be zero) for at least 2 weeks.
- Mentally competent for informed consent.
- Provided informed consent.
You may not qualify if:
- Metal objects in or around the head that cannot be removed (i.e. cochlear implant, surgical clips, piercing)
- History of seizures, or a history of seizures in first-degree relatives.
- History of eye trauma with a metal object or professional metal workers
- History of brain surgery, brain infarction, head trauma, cerebrovascular accident, broken skull, brain tumour, heart disease, cardiac pacemaker.
- Skin disease on the scalp on the position of the tDCS electrodes
- Coercive treatment based on a judicial ruling
- Pregnancy in female patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Bergenlead
- Helse-Bergen HFcollaborator
Study Sites (1)
University of Bergen
Bergen, Hordaland, 5009, Norway
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marco Hirnstein, PhD
University of Bergen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
May 6, 2016
First Posted
May 11, 2016
Study Start
July 1, 2016
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
August 7, 2020
Record last verified: 2020-08
Data Sharing
- IPD Sharing
- Will share
Data will be shared with the ERC Advanced Projects Advanced Grant #249516 "VOICE" and #693124 "ONOFF".